OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Table. 1.

T-cell/B-cell CDC and FCXM results in 251 XM-positive patients according to the presence of DSAs

T-CDC* T-AHG* B-CDC* T-FCXM B-FCXM N (%) patients (N=251) DSAs present (N=88) DSAs absent (N=163)


N (%) patients Class I DSAs Class II DSAs N (%) patients
N N N N P 2.3 (1.3−9.0) 17 (6.8) 10 (11.4) 3,458 (1,377–7,445) [5] 11,628 (2,875–37,537) [7] 7§ (4.3)
N N N P 5.0 (NA) N 1 (0.4) 0 (0.0) 1 (0.6)
N N N P 3.6 (1.3−13.6) P 3.6 (1.7−33.6) 10 (4.0) 8 (9.1) 2105 (1,071–9,740) [8] 5,541 (2,301–8,781) [2] 2 (1.2)
N N P 1:4 (NA) N N 1 (0.4) 0 (0.0) - - 1 (0.6)
N N P 1:32 (1:1−1:32) N P 3.0 (1.47−70.47) 194 (77.3) 45 (51.1) 2,541 (1,140–17,458) [21] 6,827 (1,078–28,471) [31] 149 (91.4)
N N P 1:4 (1:2−1:32) P 3.7 (1.4−5.9) P 16.7 (1.7−36.7) 5 (2.0) 3 (3.4) 4,768 (1253–8283) [2] 16,633.50 (5,756–27,511) [2] 2 (1.2)
N P N P 1.25 (NA) P 1.87 (NA) 1 (0.4) 1 (1.1) 14,084 - 0 (0.0)
N P 1:18 (1:1−1:32) P 1:18 (1:2−1:32) P 2.0 (1.3−29.4) P 2.9 (2.5−29.5) 6 (2.4) 6 (6.8) 15,154.50 (4,022–32,991) [6] 6,688.50 (4,239–9,138) [2] 0 (0.0)
P 1:4 (1:1−1:32) P 1:4 (1:1−1:32) P 1:4 (1:2−1:32) P 3.0 (1.3−94.95) P 5.5 (1.6−119.2) 16 (6.4) 15 (17.0) 16,178 (4,000–55,207) 9,040 (1,037–29,293) 1 (0.6)

*Median (range) titers are shown for positive results.Median (range) values of MFI from positive patients. There was no titer and 95% confidence interval (CI) value for only one positive patient. Median (range) MFI values of DSAs (number of patients). §B-CDC(−)/B-FCXM(+) patients. One of seven patients received rituximab treatment and were considered to have a rituximab-induced positive result. B-CDC(+)/B-FCXM(+) patients. All 149 patients received rituximab treatment and were considered to have a rituximab-induced positive result. Repeat tests showed the same results in the two patients with T-FCXM (+) only and B-CDC (+) only. Technical error could not be ruled out.

Abbreviations: XM, crossmatch; CDC, complement-dependent cytotoxicity; AHG, anti-human globulin antibody; FCXM, flow cytometric crossmatch; DSAs, donor-specific antibodies; N, negative; P, positive; NA, not available; MFI, mean fluorescent intensity.

Ann Lab Med 2021;41:429~435 https://doi.org/10.3343/alm.2021.41.4.429

© Ann Lab Med